Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1977 Feb;59(2):325–330. doi: 10.1172/JCI108644

Secretion by glucagonomas of a possible glucagon precursor.

G C Weir, E S Horton, T T Aoki, D Slovik, J Jaspan, A H Rubenstein
PMCID: PMC333363  PMID: 833279

Abstract

Five patients with glucagonomas had elevated plasma levels of total glucagon immunoreactivity. Gel filtrations of these plasma samples on Bio-Gel P30 columns showed that most of the immunoreactivity eluted in the 3,500-(true glucagon) and 9,000-dalton fractions. After the administration of alpha cell effectors, changes in total glucagon immunoreactivity were seen which were accounted for primarily by the 3,500-dalton species, but there were also changes in the 9,000-dalton moiety. Venous effluent plasma from tumors of two subjects contained elevated concentrations of glucagon immunoreactivity in both fractions. When material from both the 3,500- and 9,000-dalton peaks were serially diluted in a glucagon immunoassay, parallel displacement curves were found, suggesting that both have similar or identical antigenic determinants. Thus, with conversion to a neoplastic state, alpha cells of glucagonomas, much like beta cells of insulinomas, may secrete an increased amount of a larger, 9,000-mol wt glucagon species which may be a prohormone.

Full text

PDF
325

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buchanan K. D., McCarroll A. M. Abnormalities of glucagon metabolism in untreated diabetes mellitus. Lancet. 1972 Dec 30;2(7792):1394–1395. doi: 10.1016/s0140-6736(72)92964-9. [DOI] [PubMed] [Google Scholar]
  2. Danforth D. N., Jr, Triche T., Doppman J. L., Beazley R. M., Perrino P. V., Recant L. Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin. N Engl J Med. 1976 Jul 29;295(5):242–245. doi: 10.1056/NEJM197607292950502. [DOI] [PubMed] [Google Scholar]
  3. Day R. P., Luetscher J. A., Gonzales C. M. Occurrence of big renin in human plasma, amniotic fluid and kidney extracts. J Clin Endocrinol Metab. 1975 Jun;40(6):1078–1084. doi: 10.1210/jcem-40-6-1078. [DOI] [PubMed] [Google Scholar]
  4. Deftos L. J., Roos B. A., Bronzert D., Parthemore J. G. Immunochemical heterogeneity of calcitonin in plasma. J Clin Endocrinol Metab. 1975 Mar;40(3):409–412. doi: 10.1210/jcem-40-3-409. [DOI] [PubMed] [Google Scholar]
  5. Goodman A. D., Tanenbaum R., Rabinowitz D. Existence of two forms of immunoreactive growth hormone in human plasma. J Clin Endocrinol Metab. 1972 Dec;35(6):868–878. doi: 10.1210/jcem-35-6-868. [DOI] [PubMed] [Google Scholar]
  6. Gorden P., Hendricks C. M., Roth J. Evidence for "big" and "little" components of human plasma and pituitary growth hormone. J Clin Endocrinol Metab. 1973 Jan;36(1):178–184. doi: 10.1210/jcem-36-1-178. [DOI] [PubMed] [Google Scholar]
  7. Hellerström C., Howell S. L., Edwards J. C., Andersson A., Ostenson C. G. Biosynthesis of glucagon in isolated pancreatic islets of guinea pigs. Biochem J. 1974 Apr;140(1):13–21. doi: 10.1042/bj1400013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kuku S. F., Jaspan J. B., Emmanouel D. S., Zeidler A., Katz A. I., Rubenstein A. H. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure. J Clin Invest. 1976 Sep;58(3):742–750. doi: 10.1172/JCI108521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kuku S. F., Zeidler A., Emmanouel D. S., Katz A. I., Rubenstein A. H. Heterogeneity of plasma glucagon: patterns in patients with chronic renal failure and diabetes. J Clin Endocrinol Metab. 1976 Jan;42(1):173–176. doi: 10.1210/jcem-42-1-173. [DOI] [PubMed] [Google Scholar]
  10. Leichter S. B., Pagliara A. S., Grieder M. H., Pohl S., Rosai J., Kipnis D. M. Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma. Am J Med. 1975 Feb;58(2):285–293. doi: 10.1016/0002-9343(75)90579-3. [DOI] [PubMed] [Google Scholar]
  11. Mallinson C. N., Bloom S. R., Warin A. P., Salmon P. R., Cox B. A glucagonoma syndrome. Lancet. 1974 Jul 6;2(7871):1–5. doi: 10.1016/s0140-6736(74)91343-9. [DOI] [PubMed] [Google Scholar]
  12. McGavran M. H., Unger R. H., Recant L., Polk H. C., Kilo C., Levin M. E. A glucagon-secreting alpha-cell carcinoma of the pancreas. N Engl J Med. 1966 Jun 23;274(25):1408–1413. doi: 10.1056/NEJM196606232742503. [DOI] [PubMed] [Google Scholar]
  13. Noe B. D., Bauer G. E. Evidence of sequential metabolic cleavage of proglucagon to glucagon in glucagon biosynthesis. Endocrinology. 1975 Oct;97(4):868–877. doi: 10.1210/endo-97-4-868. [DOI] [PubMed] [Google Scholar]
  14. Noe B. D., Bauer G. E., Steffes M. W., Sutherland D. E., Najarian J. S. Glucagon biosynthesis in human pancreatic islets: preliminary evidence for a biosynthetic intermediate. Horm Metab Res. 1975 Jul;7(4):314–322. doi: 10.1055/s-0028-1093721. [DOI] [PubMed] [Google Scholar]
  15. O'Connor K. J., Lazarus N. R. Studies on the biosynthesis of pancreatic glucagon in the pigeon (Columba livia). Biochem J. 1976 May 15;156(2):279–288. doi: 10.1042/bj1560279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rigopoulou D., Valverde I., Marco J., Faloona G., Unger R. H. Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem. 1970 Feb 10;245(3):496–501. [PubMed] [Google Scholar]
  17. Valverde I., Lemon H. M., Kessinger A., Unger R. H. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma. J Clin Endocrinol Metab. 1976 May;42(5):804–808. doi: 10.1210/jcem-42-5-804. [DOI] [PubMed] [Google Scholar]
  18. Valverde I., Villanueva M. L., Lozano I., Marco J. Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon"). J Clin Endocrinol Metab. 1974 Dec;39(6):1090–1098. doi: 10.1210/jcem-39-6-1090. [DOI] [PubMed] [Google Scholar]
  19. Weir G. C., Knowlton S. D., Martin D. B. High molecular weight glucagon-like immunoreactivity in plasma. J Clin Endocrinol Metab. 1975 Feb;40(2):296–302. doi: 10.1210/jcem-40-2-296. [DOI] [PubMed] [Google Scholar]
  20. Weir G. C., Turner R. C., Martin D. B. Glucagon radioimmunoassay using antiserum 30K: interference by plasma. Horm Metab Res. 1973 Jul;5(4):241–244. doi: 10.1055/s-0028-1093958. [DOI] [PubMed] [Google Scholar]
  21. Yalow R. S., Berson S. A. Characteristics of "big ACTH" in human plasma and pituitary extracts. J Clin Endocrinol Metab. 1973 Mar;36(3):415–423. doi: 10.1210/jcem-36-3-415. [DOI] [PubMed] [Google Scholar]
  22. Yalow R. S., Berson S. A. Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins. Gastroenterology. 1970 May;58(5):609–615. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES